



PharmAust appoints trial manager and receives first \$200k installment from FightMND

- Alithia Life Sciences appointed trial manager of Phase 1 clinical trial in motor neuron disease supported by FightMND Drug Development Grant
- Monepantel (MPL) tablet production now completed to support trial and treat patients
- May trial start date on track

8 April 2022 – Perth, Australia: PharmAust Limited (ASX: PAA & PAAO), a clinical-stage biotechnology company, confirms receipt of the first installment payment from FightMND in the amount of \$201,615 for its Phase 1 motor neuron disease (MND) trial.

On 21 September 2020 PharmAust announced it received a funding commitment of \$881,085 for a Phase 1 trial examining the effects of monepantel (MPL) in MND, otherwise known as Lou Gehrig Syndrome or Amyotrophic Lateral Sclerosis (ALS).

PharmAust recently completed manufacture of cGMP (current Good Manufacturing Practice) grade MPL and therefore the milestone for the first installment payment from FightMND has been achieved.

The second installment of \$99,230 is payable after the completion of the 1-month GMP accelerated stability study of the newly prepared MPL tablets which is currently underway. The third installment of \$173,034.80 is payable upon commencement of the trial.

PharmAust is also pleased to announce the appointment of Alithia Life Sciences Pty Ltd to manage the Phase 1 trial. Alithia will provide project and site management and support of the planned study due to commence in May this year. The appointment is fully funded through the Drug Development grant awarded by FightMND.

The late May trial start date remains on track with tablet manufacture completed and stability data pending.

PharmAust's Chief Scientific Officer Dr Richard Mollard stated: "PharmAust is delighted to make this appointment to work with the highly experienced personnel at Alithia. We look forward to trial commencement and providing positive outcomes for people enrolled in the clinical trial".

This announcement is authorised by the Board.

Enquiries:

Dr Roger Aston
Executive Chairman
rogeraston@pharmaust.com

Dr Richard Mollard
Chief Scientific Officer
rmollard@pharmaust.com

P +61 (8) 9202 6814
F +61 (8) 9467 6111
W www.pharmaust.com

About PharmAust Limited:

PharmAust Limited is listed on the Australian Securities Exchange (code: PAA) and the Frankfurt Stock Exchange (code: ECQ). PAA is a clinical-stage company developing therapeutics for both humans and animals. The company specialises in repurposing marketed drugs lowering the risks and costs of development. These efforts are supported by PAA's subsidiary, Epichem, a highly successful contract medicinal chemistry company that generated \$2.2 million in sales of goods & services in FY 2021.

PAA's lead drug candidate is monepantel (MPL), a novel, potent and safe inhibitor of the mTOR pathway – a pathway having key influences in cancer growth and neurodegenerative diseases. MPL has been evaluated in Phase 1 clinical trials in humans and Phase 2 clinical trials in dogs. MPL treatment was well-tolerated in humans, demonstrating preliminary evidence of anticancer activity. MPL demonstrated objective anticancer activity in dogs. PAA is uniquely positioned to commercialise MPL for treatment of human and veterinary cancers as well as neurodegenerative disease as it advances a reformulated version of this drug through Phase 1 and 2 clinical trials.

About FightMND:

Founded in 2014, FightMND was established in Australia with the purpose of finding effective treatments and ultimately a cure for Motor Neuron Disease (MND), also referred to as ALS or Lou Gehrig's Disease. FightMND, with its vision of a world without MND, is the largest independent funder of MND research in Australia. Since 2014, FightMND has investment more than \$63 million into MND research and care equipment to improve the lives of those fighting the disease. FightMND is determined to help facilitate the translation of the growing body of new knowledge about the disease into a cure for MND patients in Australia and abroad.

For more information about FightMND, visit the website at <https://fightmnd.org.au>.